Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancerR Charles Coombes, Judith M Bliss, Marc Espie, et al.
The Lancet. Oncology|September 24, 2013
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trialsJoanne S Haviland, J Roger Owen, John A Dewar, et al.
The Lancet. Oncology|June 14, 2025
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trialAnna M Kirby, Laura Finneran, Clare L Griffin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
The Lancet. Oncology|June 5, 2019
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trialIan Judson, James P Morden, Lucy Kilburn, et al.
Breast Cancer Research and Treatment|May 17, 2018
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancerErik J Blok, Charla C Engels, Geeske Dekker-Ensink, et al.
Lancet (London, England)|May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialPaul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
The Lancet. Oncology|August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialStephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Pageof 10